The researchers, led by Qingyu Zhang and Xiaolin Lu of the Capital Institute of Pediatrics together with colleagues at Capital Medical University, the Chinese People’s Liberation Army General Hospital Eastern Medical Branch, and Beijing University of Technology, combined metabolomics with transcriptome-wide sequencing to interrogate both sides of the puzzle at once. On the metabolic side, they used mass spectrometry to measure concentrations of amino acids and related metabolites in the serum of women with anembryonic pregnancy and compared those profiles against healthy pregnant controls. On the genomic side, they sequenced RNA from chorionic villi, the placental precursor tissue obtained from the affected pregnancies, and used a computational tool called rMATS to systematically catalog differences in alternative splicing between patients and controls.

Alternative splicing is the cell’s strategy for squeezing remarkable diversity out of a finite genome. After a gene is transcribed into precursor messenger RNA, segments called exons can be stitched together in different combinations while others are skipped, producing protein variants with distinct functions. The process is a fundamental driver of development and tissue identity, and errors in splicing have been implicated in conditions ranging from neurodegenerative disease to cancer. Previous work had already hinted that splicing matters in reproduction: animal studies have shown that splicing regulators shape placental growth, and disruptions of splicing factors have been linked to impaired placental development and spontaneous abortion in experimental models. What remained unknown was whether splicing defects contribute to the metabolic disturbances characteristic of anembryonic pregnancy specifically.

The scale of the splicing disruption the team documented was striking. Compared with healthy controls, patients with anembryonic pregnancy carried 903 genes showing differential alternative splicing and 558 differentially expressed genes. Among the splicing changes, exon skipping emerged as the predominant event type, meaning that in the affected tissue, specific exon segments were disproportionately excluded from the mature messenger RNA. Mass spectrometry independently confirmed that amino acid metabolism was indeed dysregulated in the patients’ serum, consistent with earlier metabolomic studies of early pregnancy loss and reinforcing the idea that the metabolic environment of the pregnancy goes awry when embryonic development fails.

Three genes stood out from the splicing analysis with the most significant alterations: PRKCD, which encodes a protein kinase involved in cell signaling and apoptosis; SCARB1, the scavenger receptor class B member 1 that serves as the major cell-surface receptor for high-density lipoprotein cholesterol; and METTL2B, a member of the methyltransferase family. In all three, the affected samples showed preferential exon inclusion rather than skipping, a shift that would change the protein products these genes yield in the chorionic villi. The team validated these findings using splicing-specific polymerase chain reaction, a technique that amplifies and distinguishes the exon-included and exon-excluded transcript forms, confirming that the sequencing results reflected genuine biological differences rather than computational artifacts.

The choice of SCARB1 as a headline finding carries considerable biological weight. The receptor it encodes, often called SR-BI, was identified in landmark work in the 1990s as the high-density lipoprotein receptor, and it plays a well-established role in cholesterol homeostasis. Intriguingly, prior research in mice had already shown that the splicing regulator RBFOX2 in the liver controls cholesterol levels by modulating Scarb1 alternative splicing, and independent studies have tied SR-BI to metabolic phenotypes in other contexts. The new study extends that logic to human early pregnancy, suggesting that when SCARB1 splicing goes wrong in chorionic villi, the consequences ripple outward into both lipid and amino acid metabolism.

To understand what might be driving the splicing changes, the investigators turned to motif analysis, a computational approach that searches DNA sequences near splicing events for binding signatures of transcription factors. The analysis predicted that SCARB1 is a potential target gene of TEAD4, a transcription factor with an established and critical role in early embryology. TEAD4 is a key effector of the Hippo signaling pathway, and in mouse studies it is required for the specification of the trophectoderm, the cell lineage that gives rise to the placenta. Work in human preimplantation embryos has similarly shown that TEAD4 regulates trophectoderm differentiation upstream of the gene CDX2, and separate research has demonstrated that loss of TEAD4 function impairs postimplantation development and has been implicated in early human pregnancy loss.

Functional experiments in the new study revealed that both SCARB1 and TEAD4 participate in the regulation of metabolism, including amino acid and lipid metabolism, linking the transcriptional regulator, its predicted splicing-sensitive target, and the metabolic derangements measured in patient serum into a coherent mechanism. The authors further examined correlations between the degree of SCARB1 exon exclusion and the serum concentrations of nineteen amino acids and metabolites, integrating transcription factor prediction with publicly available datasets to build a picture of how splicing-mediated changes could feed into systemic metabolic disruption. Protein-protein interaction analysis of pregnancy-related TEAD4 targets undergoing exon-skipping events added another layer, highlighting placenta-expressed genes within this regulatory network.

The study’s implications cut in two directions. Scientifically, it elevates alternative splicing-mediated metabolic reprogramming from a suspected mechanism to a documented feature of anembryonic pregnancy, connecting a transcription factor central to trophectoderm specification, a cholesterol receptor with newly appreciated metabolic reach, and the amino acid disturbances measurable in maternal blood. Clinically, the findings suggest potential avenues that were previously invisible: if the splicing pattern of SCARB1 or the serum amino acid profile proves robust in larger cohorts, such molecular signatures could eventually inform earlier diagnosis of anembryonic pregnancy or point toward metabolic interventions, although the authors’ work remains at the mechanistic stage and no diagnostic or therapeutic application follows directly from these results.

Important caveats temper the enthusiasm. The validation experiments compared eight patients with eight controls, a sample size that underscores the need for replication in larger and more diverse populations before the SCARB1-TEAD4 axis can be considered a confirmed driver of anembryonic pregnancy rather than a strongly supported hypothesis. The study also documents correlation and predicted regulation rather than demonstrating, through direct perturbation experiments, that correcting SCARB1 splicing rescues metabolic function. The RNA sequencing datasets have been deposited in the National Genomics Data Center under accession PRJCA041061, allowing other researchers to interrogate the data independently, and the work received support from the Beijing Research Ward Excellence Program, the National Natural Science Fund of Beijing, and the National Natural Science Foundation of China. Even with these limitations, the study marks a meaningful step toward explaining why some pregnancies stall before the embryo ever develops, and it reframes early pregnancy loss as a disorder that can begin with a misstep in how RNA is cut and pasted.

Subject of Research: The role of SCARB1 alternative splicing in amino acid metabolism dysregulation in anembryonic pregnancy

Article Title: Dysregulation of SCARB1 Alternative Splicing Disturbs Amino Acid Metabolism in Anembryonic Pregnancy

Article References: Zhang, Q., Wu, X., Liu, X., Wei, J., Wang, L., Cao, J., & Lu, X. (2026). Dysregulation of SCARB1 Alternative Splicing Disturbs Amino Acid Metabolism in Anembryonic Pregnancy. Reproductive Sciences. https://doi.org/10.1007/s43032-026-02179-4

Image Credits: AI Generated

DOI: 10.1007/s43032-026-02179-4

Keywords: anembryonic pregnancy, alternative splicing, SCARB1, TEAD4, amino acid metabolism, chorionic villi, RNA sequencing, miscarriage, metabolomics, transcription factors, early pregnancy loss, reproductive biology

The study, led by Emily A. Clarke of the Icahn School of Medicine at Mount Sinai and Reproductive Medicine Associates of New York, together with colleagues including Alan B. Copperman, examined 203 patients who experienced early pregnancy loss and subsequently underwent a single euploid embryo transfer, a procedure in which a genetically screened embryo with the correct number of chromosomes is transferred one at a time. Of these patients, 88 were managed medically, typically with misoprostol, while 115 underwent surgical management, usually dilation and curettage. Because all participants received embryos confirmed to be chromosomally normal through preimplantation genetic testing, the researchers were able to isolate the contribution of the uterine environment itself, removing the confounding noise of embryo aneuploidy, which is the leading cause of early miscarriage and failed implantation.

The primary outcome was the change in endometrial thickness between the cycle in which the pregnancy was lost and the subsequent frozen embryo transfer cycle. Endometrial thickness, measured by transvaginal ultrasound, is one of the most closely watched parameters in reproductive medicine because a lining thinner than seven millimeters is associated with markedly reduced implantation and live birth rates. Large analyses of tens of thousands of embryo transfers, including a 2022 study of more than 96,000 autologous transfers published in Fertility and Sterility, have demonstrated a graded relationship between lining thickness and success, making any iatrogenic thinning of the endometrium a legitimate clinical concern.

What the researchers found was striking in its neutrality. Between the initial and subsequent transfer cycles, endometrial thickness changed by an average of plus 0.3 millimeters in the medically managed group and plus 0.1 millimeters in the surgically managed group, a difference that was statistically indistinguishable with a P value of 0.65. In the subsequent transfer cycle itself, the average lining measured 9.4 millimeters in the medical group and 9.1 millimeters in the surgical group, again with no significant difference. Cycle cancellation because of a persistently thin lining, defined as less than seven millimeters, was rare in both arms, occurring in 3.4 percent of medically managed patients and 2.6 percent of surgically managed patients. In practical terms, the surgical instrumentation that many feared might scar the uterine cavity did not measurably impair the endometrium’s ability to proliferate under hormonal preparation.

This finding carries particular weight because prior literature had raised genuine alarms. Earlier studies, including work by Shufaro and colleagues in 2008 and investigations by Davar and Azumaguchi, described a thin, unresponsive endometrium as a possible complication of surgical curettage, with some patients developing linings that failed to thicken even with high doses of estrogen. Asherman’s syndrome, the formation of intrauterine adhesions after aggressive curettage, remains a recognized and sometimes devastating consequence of uterine instrumentation. The new data do not erase those risks, which are uncommon but real, yet they suggest that in the specific population of IVF patients destined for euploid embryo transfer, routine dilation and curettage for early pregnancy loss does not produce a detectable average penalty on endometrial development.

The secondary outcomes told a more nuanced story. While live birth rates in the subsequent transfer cycle were statistically similar between the two groups, 48.8 percent among medically managed patients versus 40.7 percent among surgically managed patients, the rate of clinical pregnancy loss after a positive pregnancy test was significantly higher in the surgical cohort, at 15.7 percent compared with 4.9 percent. After adjusting for potential confounders, surgical management carried an adjusted odds ratio of 3.72 for subsequent pregnancy loss, with a 95 percent confidence interval of 1.11 to 12.47. The authors stopped short of claiming causation, and the absolute difference, roughly eleven percentage points, is modest, but the signal is biologically plausible. Instrumentation of the uterine cavity could theoretically alter the endometrium’s receptivity at a level finer than thickness alone can capture, affecting the molecular dialogue between embryo and lining that governs implantation and placentation.

Endometrial receptivity is a complex process involving the synchronized expression of hundreds of genes, the maturation of the epithelial pinopodes, the recruitment of immune cells, and the development of an adequate blood supply. Research into implantation failure has implicated inflammatory markers and disruptions of this delicate immunological environment. A curettage procedure induces a controlled injury and an inflammatory repair response, and while the lining may regenerate to a normal thickness, subtle alterations in its functional quality could persist. The elevated miscarriage rate observed in the surgical group, despite equivalent lining measurements and equivalent live birth rates among those pregnancies that did progress, hints at exactly this kind of subclinical functional difference, one that ultrasound cannot see but that may manifest as an early pregnancy that implants and then fails.

The study’s design deserves scrutiny. As a single-center retrospective cohort, it cannot randomize patients to treatment arms, and the choice between medical and surgical management was made by patients and physicians based on clinical circumstances, introducing the possibility of selection bias. Patients with heavier bleeding, retained tissue, or hemodynamic instability are more likely to undergo surgery, and these same factors might independently affect subsequent reproductive outcomes. The sample size of 203, while respectable for a single-center study, limits statistical power for rare outcomes, and the wide confidence interval around the miscarriage odds ratio reflects that uncertainty. Nevertheless, the use of euploid single embryo transfers represents a methodological strength that few prior studies on this question have enjoyed, because it controls for the single largest determinant of IVF success, namely embryo chromosomal competence.

For clinicians, the findings translate into a more evidence-based framework for counseling. Patients with early pregnancy loss who have frozen euploid embryos waiting can be told that neither medical nor surgical management appears to compromise their endometrial thickness or their overall chances of a live birth in the next transfer cycle. Those who prefer the certainty and speed of a surgical procedure, or who require it for clinical reasons, can be reassured that the lining typically recovers fully. At the same time, the elevated loss rate in the surgical group gives clinicians a legitimate data point to discuss, particularly for patients with a history of recurrent pregnancy loss who may be especially sensitive to any factor that raises miscarriage risk. The decision should remain individualized, weighing the efficacy, side effects, and completion rates of misoprostol against the operating room requirements of curettage.

The research, presented orally at the American Society for Reproductive Medicine’s scientific congress in Denver in October 2024 before its peer-reviewed publication, adds to a growing body of work aimed at demystifying what happens to the uterus after miscarriage and how best to prepare it for the next attempt. Early pregnancy loss affects roughly one in ten recognized pregnancies, and among IVF patients the emotional and financial stakes of each subsequent cycle are exceptionally high. By demonstrating that endometrial recovery is robust across both management pathways, and by flagging a modest but significant difference in subsequent pregnancy loss, the study gives patients and physicians something they have long lacked: quantitative, embryo-quality-controlled evidence on which to base one of the most common and consequential decisions in reproductive medicine. The authors note that de-identified data are available upon reasonable request, and they emphasize that these findings may help guide counseling for patients navigating the difficult intersection of miscarriage management and fertility treatment.

Subject of Research: How medical versus surgical management of early pregnancy loss affects endometrial thickness and outcomes of subsequent euploid embryo transfers in IVF patients

Article Title: Management of Early Pregnancy Loss: Reproductive Outcome in Subsequent Euploid Embryo Transfers

Article References: Management of Early Pregnancy Loss: Reproductive Outcome in Subsequent Euploid Embryo Transfers. (n.d.). https://doi.org/10.1007/s43032-026-02200-w

Image Credits: AI Generated

DOI: 10.1007/s43032-026-02200-w

Keywords: early pregnancy loss, dilation and curettage, misoprostol, endometrial thickness, euploid embryo transfer, in vitro fertilization, live birth rate, clinical pregnancy loss, reproductive medicine, miscarriage management, Management, Early